The Use of Ischemia-modified Albumin(IMA) in Ischemic Stroke
INTRODUCTION: The aim of this study was to investigate the possibility of ischemiamodified albumin (IMA) as a new and rapid diagnostic biomarker of ischemic stroke and compare IMA in progression of stroke and non-progression of ischemic stroke. METHODS: Fifty-two emergency patients with acute neurologic symptoms were admitted to the emergency department within 6 hours of symptom onset (28 Ischemic Stroke Group; SG, 24 Non-Stroke Group; NSG). Blood samples for IMA measurements by albumin cobalt binding test (Ischemia Technology, Denver, U.S.A) were obtained at arrival, and 12 and 24 hours after the onset of symptoms. RESULTS: The initial mean IMA level was 107.4 (107.4±11.0) U/ml in SG and 86.5 (86.5±8.5) U/ml in NSG, respectively (p <0.001). Fifteen SG patients showed progression. The difference between the two groups in IMA level according to time was not statistically significant (p > 0.05). CONCLUSION: IMA may be a new diagnostic biomarker in ischemic stroke. However, it is difficult to be used as a predictive biomarker for progression of ischemic stroke.
Ischemia-modified albumin, Ischemia, Ischemic stroke, 허혈, 허혈성 뇌질환
Networked Digital Library of Theses and Dissertations